These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12965080)

  • 1. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
    Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
    J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
    Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
    Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
    Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
    Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
    Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
    Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
    Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
    Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
    Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
    Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
    Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
    Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.
    Corrias MV; Faulkner LB; Pistorio A; Rosanda C; Callea F; Piccolo MS; Scaruffi P; Marchi C; Lacitignola L; Occhino M; Gambini C; Tonini GP; Haupt R; De Bernardi B; Pistoia V; Garaventa A
    Clin Cancer Res; 2004 Dec; 10(23):7978-85. PubMed ID: 15585633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA.
    Miyajima Y; Horibe K; Fukuda M; Matsumoto K; Numata S; Mori H; Kato K
    Cancer; 1996 Mar; 77(6):1214-9. PubMed ID: 8635146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
    Shono K; Tajiri T; Fujii Y; Suita S
    J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
    Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
    Fukuda M; Miyajima Y; Miyashita Y; Horibe K
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.
    Swerts K; De Moerloose B; Dhooge C; Vandesompele J; Hoyoux C; Beiske K; Benoit Y; Laureys G; Philippé J
    Clin Chem; 2006 Mar; 52(3):438-45. PubMed ID: 16384890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma.
    Chambon F; Tchirkov A; Pereira B; Rochette E; Deméocq F; Kanold J
    Pediatr Blood Cancer; 2013 Sep; 60(9):E109-12. PubMed ID: 23596146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.
    Bochennek K; Esser R; Lehrnbecher T; Glienke W; Wehner S; Erben S; Soerensen J; Schwabe D; Bader P; Klingebiel T; Koehl U
    Klin Padiatr; 2012 Apr; 224(3):139-42. PubMed ID: 22377741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.